IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line plus , metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG